Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

Brian Hess; Nina D. Wagner-Johnston; Lindsey Hendrickson; James A. Davis; Elizabeth Hill; Anshu Giri; Kent Armeson; Maria V. Revuelta; Shanta Salzer; Robin Klingenberg; Leandro Cerchietti

doi:10.1007/s00277-026-07125-7

Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

Brian Hess
, Nina D. Wagner-Johnston
, Lindsey Hendrickson
, James A. Davis
, Elizabeth Hill
, Anshu Giri
, Kent Armeson
, Maria V. Revuelta
, Shanta Salzer
, Robin Klingenberg
, Leandro Cerchietti

Hematology Oncology

Hollings Cancer Center
Johns Hopkins University
New York University

Research output: Contribution to journal › Article › peer-review

Abstract

Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.

Original language	English
Article number	405
Journal	Annals of Hematology
Volume	105
Issue number	9
Early online date	Jun 22 2026
DOIs	https://doi.org/10.1007/s00277-026-07125-7 https://doi.org/10.1007/s00277-026-07125-7
State	Published - Sep 2026

Keywords

Dlbcl
Epigenetics
Lymphoma

Access to Document

Cite this

Hess, B., Wagner-Johnston, N. D., Hendrickson, L., Davis, J. A., Hill, E., Giri, A., Armeson, K., Revuelta, M. V., Salzer, S., Klingenberg, R., & Cerchietti, L. (2026). Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma. Annals of Hematology, 105(9), Article 405. https://doi.org/10.1007/s00277-026-07125-7, https://doi.org/10.1007/s00277-026-07125-7

@article{cd8c8818a41d43bba32dae06304d0c9b,

title = "Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma",

abstract = "Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.",

keywords = "Dlbcl, Epigenetics, Lymphoma",

author = "Brian Hess and Wagner-Johnston, \{Nina D.\} and Lindsey Hendrickson and Davis, \{James A.\} and Elizabeth Hill and Anshu Giri and Kent Armeson and Revuelta, \{Maria V.\} and Shanta Salzer and Robin Klingenberg and Leandro Cerchietti",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026.",

year = "2026",

month = sep,

doi = "10.1007/s00277-026-07125-7",

language = "English",

volume = "105",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "9",

}

Hess, B, Wagner-Johnston, ND, Hendrickson, L, Davis, JA, Hill, E, Giri, A, Armeson, K, Revuelta, MV, Salzer, S, Klingenberg, R & Cerchietti, L 2026, 'Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma', Annals of Hematology, vol. 105, no. 9, 405. https://doi.org/10.1007/s00277-026-07125-7, https://doi.org/10.1007/s00277-026-07125-7

TY - JOUR

T1 - Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

AU - Hess, Brian

AU - Wagner-Johnston, Nina D.

AU - Hendrickson, Lindsey

AU - Davis, James A.

AU - Hill, Elizabeth

AU - Giri, Anshu

AU - Armeson, Kent

AU - Revuelta, Maria V.

AU - Salzer, Shanta

AU - Klingenberg, Robin

AU - Cerchietti, Leandro

PY - 2026/9

Y1 - 2026/9

N2 - Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.

AB - Salvage chemotherapy and autologous stem cell transplantation (ASCT) offer the opportunity to cure eligible patients with relapsed diffuse large B-cell lymphoma (DLBCL). Epigenetic alterations such as aberrant DNA methylation patterns have been linked to chemotherapy resistance in DLBCL. Oral Azacitadine (AZA) is a hypomethylating agent that inhibits DNA methyltransferase and has provided evidence of chemotherapy sensitization in DLBCL. In this phase I trial the safety and feasibility of two dose levels of AZA were investigated in combination with standard cytotoxic chemotherapy rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in relapsed DLBCL patients who were candidates for ASCT.

KW - Dlbcl

KW - Epigenetics

KW - Lymphoma

UR - https://www.scopus.com/pages/publications/105049119359

U2 - 10.1007/s00277-026-07125-7

DO - 10.1007/s00277-026-07125-7

M3 - Article

C2 - 42324342

SN - 0939-5555

VL - 105

JO - Annals of Hematology

JF - Annals of Hematology

IS - 9

M1 - 405

ER -

Phase I study of oral azacitidine plus salvage chemotherapy in relapsed/refractory diffuse large B-cell lymphoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this